Clinical trial considerations on male contraception and collection of pregnancy information from female partners.
Level 5 - mechanism / opinion, no new human data
Expert opinion and regulatory framework based on mechanism and preclinical extrapolation without primary clinical data
PubMed 22720695 · doi:10.1186/1479-5876-10-129
What was done
The authors synthesized pharmacological and toxicological principles to propose standardized clinical trial guidance on male contraception requirements and pregnancy data collection for female partners of male participants exposed to genotoxic, teratogenic, or uncharacterized investigational drugs.
What was found
For genotoxic compounds, condom use is required during exposure and for 5 terminal plasma half-lives plus 74 days (one human spermatogenesis cycle). For non-genotoxic small molecules and immunoglobulins of unknown teratogenicity lacking an embryo-fetal development no observed adverse effect level (NOAEL) or minimal anticipated biological effect level (MABEL), condom use is recommended for male participants with pregnant partners or partners of childbearing potential. For teratogenic small molecules, condom use is not required if the margin between projected maternal AUC and NOAEL AUC is >=300 (>=100 for immunoglobulins), or if the margin between MABEL plasma concentration and maternal Cmax is >=300 (>=10 for immunoglobulins). If seminal fluid concentrations are directly measured, the safety margin threshold requiring condom use for small molecules decreases from <300 to <100. Proactive pregnancy data collection is recommended for first-in-class agents or embryofetotoxic drug classes. The abstract reports no empirical human outcome numbers.
Why it matters
This framework establishes standardized, margin-based criteria to mitigate potential seminal drug transfer risks to female partners and fetuses during clinical trials.
Limits
The recommendations represent expert consensus and theoretical extrapolations from preclinical models rather than primary human clinical trial data. No clinical pregnancy outcomes, actual seminal transfer measurements, or protocol compliance rates were tested or reported.
Cited by
- context The lifespan of sperm is approximately 90 days, and the human egg is most susceptible to environmental influences during the 60 days prior to conception.